DK2880053T3 - Lindring af vævsskade og fibrose via anti-LTBP4-antistof - Google Patents

Lindring af vævsskade og fibrose via anti-LTBP4-antistof Download PDF

Info

Publication number
DK2880053T3
DK2880053T3 DK13835243.0T DK13835243T DK2880053T3 DK 2880053 T3 DK2880053 T3 DK 2880053T3 DK 13835243 T DK13835243 T DK 13835243T DK 2880053 T3 DK2880053 T3 DK 2880053T3
Authority
DK
Denmark
Prior art keywords
relief
tissue damage
via anti
fibrosis via
ltbp4
Prior art date
Application number
DK13835243.0T
Other languages
English (en)
Inventor
Elisabeth M Mcnally
Ahlke Heydemann
Ermelinda Ceco
Original Assignee
Ikaika Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ikaika Therapeutics Llc filed Critical Ikaika Therapeutics Llc
Application granted granted Critical
Publication of DK2880053T3 publication Critical patent/DK2880053T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK13835243.0T 2012-08-01 2013-08-01 Lindring af vævsskade og fibrose via anti-LTBP4-antistof DK2880053T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261678564P 2012-08-01 2012-08-01
PCT/US2013/053255 WO2014039189A1 (en) 2012-08-01 2013-08-01 Mitigating tissue damage and fibrosis via latent transforming growth factor beta binding protein (ltbp4)

Publications (1)

Publication Number Publication Date
DK2880053T3 true DK2880053T3 (da) 2020-05-11

Family

ID=50025687

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13835243.0T DK2880053T3 (da) 2012-08-01 2013-08-01 Lindring af vævsskade og fibrose via anti-LTBP4-antistof

Country Status (14)

Country Link
US (12) US9873739B2 (da)
EP (3) EP4678239A3 (da)
AU (6) AU2013313282B2 (da)
CA (1) CA2880649C (da)
CY (1) CY1123029T1 (da)
DK (1) DK2880053T3 (da)
ES (2) ES2791778T3 (da)
HR (1) HRP20200818T1 (da)
HU (1) HUE049217T2 (da)
PL (1) PL2880053T3 (da)
PT (1) PT2880053T (da)
RS (1) RS60318B1 (da)
SI (1) SI2880053T1 (da)
WO (1) WO2014039189A1 (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY186389A (en) * 2014-05-13 2021-07-22 Univ Pennsylvania Compositions comprising aav expressing dual antibody constructs and uses thereof
WO2016054155A1 (en) * 2014-09-30 2016-04-07 Primegen Biotech, Llc. Treatment of fibrosis using deep tissue heating and stem cell therapy
KR20160101692A (ko) 2015-02-17 2016-08-25 한국전자통신연구원 다채널 신호 처리 방법 및 상기 방법을 수행하는 다채널 신호 처리 장치
EA201792500A1 (ru) 2015-05-13 2018-04-30 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Aav-опосредованная экспрессия антител против гриппа и способы их использования
MX2019010275A (es) 2017-02-28 2019-10-15 Univ Pennsylvania Novedoso vector del subtipo f del virus adenoasociado (aav) y usos de este.
JOP20190200A1 (ar) 2017-02-28 2019-08-27 Univ Pennsylvania تركيبات نافعة في معالجة ضمور العضل النخاعي
BR112019017697A2 (pt) 2017-02-28 2020-04-07 The Trustees Of The University Of Pennsylvania vacinas contra influenza baseadas em vetores de vírus adenoassociado (aav)
US20220193250A1 (en) 2018-08-02 2022-06-23 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
JP7611825B2 (ja) 2018-08-02 2025-01-10 ダイン セラピューティクス，インコーポレーテッド ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
WO2020132647A1 (en) 2018-12-21 2020-06-25 Northwestern University Use of annexins in preventing and treating muscle membrane injury
WO2020139977A1 (en) 2018-12-26 2020-07-02 Northwestern University Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
KR20250159196A (ko) * 2023-02-27 2025-11-10 다인 세라퓨틱스, 인크. 근육내 섬유증의 진행을 억제하기 위한 방법 및 조성물

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
US5372807A (en) 1990-05-14 1994-12-13 University Of Medicine And Dentistry Of New Jersey Polymers containing antifibrotic agents, compositions containing such polymers, and methods of preparation and use
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US5637459A (en) 1990-06-11 1997-06-10 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chimeric selex
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5994618A (en) 1997-02-05 1999-11-30 Johns Hopkins University School Of Medicine Growth differentiation factor-8 transgenic mice
ES2201076T3 (es) 1993-03-19 2004-03-16 The Johns Hopkins University School Of Medicine Factor-8 de diferenciacion del crecimiento.
US6891082B2 (en) 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
US6369201B1 (en) 1998-02-19 2002-04-09 Metamorphix International, Inc. Myostatin multimers
US6004937A (en) 1998-03-09 1999-12-21 Genetics Institute, Inc. Use of follistatin to modulate growth and differentiation factor 8 [GDF-8] and bone morphogenic protein 11 [BMP-11]
NZ513642A (en) 1999-01-21 2004-02-27 Metamorphix Inc Growth differentiation factor inhibitors and uses therefor
JP2002541253A (ja) 1999-04-09 2002-12-03 スミスクライン・ビーチャム・コーポレイション トリアリールイミダゾール
SK722002A3 (en) 1999-07-20 2003-02-04 Pharmexa As Method for down-regulating GDF-8 activity
US7368534B2 (en) 2000-01-18 2008-05-06 Orico Limited Myostatin and mimetics thereof
CO5271680A1 (es) 2000-02-21 2003-04-30 Smithkline Beecham Corp Compuestos
GB0007405D0 (en) 2000-03-27 2000-05-17 Smithkline Beecham Corp Compounds
EP1191097A1 (en) 2000-09-21 2002-03-27 Leids Universitair Medisch Centrum Induction of exon skipping in eukaryotic cells
US20040039198A1 (en) 2000-11-16 2004-02-26 Bender Paul E. Compounds
GB0102668D0 (en) 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
TWI329129B (en) 2001-02-08 2010-08-21 Wyeth Corp Modified and stabilized gdf propeptides and uses thereof
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
JP4429728B2 (ja) 2002-02-21 2010-03-10 ワイス エルエルシー フォリスタチン（ｆｏｌｌｉｓｔａｔｉｎ）ドメイン含有タンパク質
BR0307907A2 (pt) 2002-02-21 2011-07-05 Wyeth Corp gasp1: proteìna contendo domìnio de folistatina
EP1578928B1 (en) 2002-09-16 2010-03-17 The Johns Hopkins University Metalloprotease activation of myostatin, and methods of modulating myostatin activity
US7261893B2 (en) 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
US20040223966A1 (en) 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
KR20110086881A (ko) 2002-12-20 2011-08-01 암겐 인코포레이티드 미오스타틴을 저해하는 결합제
WO2004083241A2 (en) * 2003-03-19 2004-09-30 Takeda Pharmaceutical Company Limited Btc-interacting proteins and use thereof
US7456149B2 (en) 2004-03-02 2008-11-25 Acceleron Pharma, Inc. ALK7 and myostatin inhibitors and uses thereof
US20070178095A1 (en) 2004-03-23 2007-08-02 Eli Lilly And Company Anti-myostatin antibodies
PL1766010T3 (pl) 2004-06-28 2011-07-29 Univ Western Australia Antysensowne oligonukleotydy do indukcji pominięcia egzonu i sposoby ich zastosowania
EP3489257A1 (en) 2004-07-23 2019-05-29 Acceleron Pharma Inc. Actrii receptor polypeptides, methods and compositions
CA2576734C (en) 2004-07-29 2010-03-16 Schering-Plough Ltd. Use of alk 5 inhibitors to modulate or inhibit myostatin activity leading to increased lean tissue accretion in animals
EP1877075A4 (en) 2005-04-25 2008-07-30 Pfizer ANTIBODY TO MYOSTATIN
WO2010009368A2 (en) * 2008-07-18 2010-01-21 Oragenics, Inc. Compositions for the detection and treatment of colorectal cancer
US8084601B2 (en) 2008-09-11 2011-12-27 Royal Holloway And Bedford New College Royal Holloway, University Of London Oligomers
FR2943249B1 (fr) 2009-03-18 2011-08-12 Genethon Utilisation de la decorine pour augmenter la masse musculaire
US20120039806A1 (en) 2009-03-23 2012-02-16 Mireille Hanna Lahoud Compounds and Methods for Modulating an Immune Response
WO2010129861A2 (en) 2009-05-08 2010-11-11 Curna, Inc. Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to dmd family
WO2012006181A2 (en) 2010-06-29 2012-01-12 Mount Sinai School Of Medicine Compositions and methods for inhibiting oncogenic micrornas and treatment of cancer

Also Published As

Publication number Publication date
EP2880053A1 (en) 2015-06-10
EP3711771C0 (en) 2025-09-03
EP2880053B1 (en) 2020-02-26
AU2021200783B2 (en) 2022-10-06
CY1123029T1 (el) 2021-10-29
ES2791778T3 (es) 2020-11-05
ES3047691T3 (en) 2025-12-04
EP4678239A3 (en) 2026-04-08
EP4678239A2 (en) 2026-01-14
US20200123247A1 (en) 2020-04-23
US20190002557A1 (en) 2019-01-03
US20250346664A1 (en) 2025-11-13
US20200385457A1 (en) 2020-12-10
US20210238274A1 (en) 2021-08-05
EP3711771B1 (en) 2025-09-03
EP3711771A1 (en) 2020-09-23
CA2880649A1 (en) 2014-03-13
AU2022271391A1 (en) 2022-12-15
SI2880053T1 (sl) 2020-08-31
PL2880053T3 (pl) 2021-01-11
RS60318B1 (sr) 2020-07-31
AU2013313282A1 (en) 2015-02-26
HRP20200818T1 (hr) 2020-08-07
US20230235044A1 (en) 2023-07-27
US20240287171A1 (en) 2024-08-29
US20190256589A1 (en) 2019-08-22
AU2021200783A1 (en) 2021-03-04
EP2880053A4 (en) 2016-03-09
HK1211307A1 (en) 2016-05-20
AU2018200078A1 (en) 2018-01-25
AU2013313282B2 (en) 2018-02-01
US20140037637A1 (en) 2014-02-06
US9873739B2 (en) 2018-01-23
PT2880053T (pt) 2020-05-22
CA2880649C (en) 2023-03-14
US20180134785A1 (en) 2018-05-17
AU2024204925A1 (en) 2024-08-08
WO2014039189A1 (en) 2014-03-13
EP2880053B8 (en) 2020-04-15
US20220089717A1 (en) 2022-03-24
AU2019222850A1 (en) 2019-09-19
HUE049217T2 (hu) 2020-09-28
US20250109197A1 (en) 2025-04-03

Similar Documents

Publication Publication Date Title
IL269045A (en) Aptamers and uses thereof
DK2521221T4 (da) Høreanordning og fremgangsmåde
DK2882496T3 (da) Behandling og diagnosticering af melanom
DK2850202T3 (da) Fremgangsmåder og grupper
DK3608325T3 (da) Polycykliske-carbamoylpyridonforbindelser og deres farmaceutiske anvendelse
DK4389764T3 (da) Genetisk modificerede gnavere og fremgangsmåder til anvendelse heraf
BR112014001561A2 (pt) região de mémoria temporária real variável e aparelho
DK3597644T3 (da) Kationiske aminlipider og anvendelser deraf
IL227465B (en) Blockstent device amd methods of use
DK2794654T3 (da) Anti-phf-tau-antistoffer og deres anvendelser
PL2922850T3 (pl) Związki i sposoby ich stosowania
EP2870505A4 (en) TRANSPARENT GLOSS AND GLOSS PROTECTION STRUCTURES
IL235590A0 (en) Phototherapy devices and methods
DK2855736T3 (da) Elektrolysator og energisystem
DK3003039T3 (da) Methyl/fluor-pyridinyl-metoxy-substituerede pyridinon-pyridinyl-forbindelser og fluor-pyrimidinyl-metoxy-substituerede pyridinon-pyridinyl-forbindelser
DK2609956T3 (da) Midlertidigt foldbart kateteraggregat og dertil hørende fremgangsmåde
DK2914291T3 (da) Anti-komplement-c1s-antistoffer og anvendelser deraf
DK2903600T3 (da) Virusholdig formulering og anvendelse deraf
DK3415157T3 (da) N-acyldipeptidderivater og anvendelser deraf
DK3333188T3 (da) Anti-NGF-antistoffer og deres anvendelse
BR112012031446A2 (pt) componentes e métodos para implantes
BR112014030410A2 (pt) inibidores de pirazolopirimidona e pirazolopiridona de tanquirase
DK2806892T3 (da) Kombineret terapeutisk anvendelse af antistoffer og endoglycosidaser
DK2882441T3 (da) Behandling af immunrelaterede og inflammatoriske sygdomme
BR112012031130A2 (pt) métodos e dispositivos para filtração